Discover 1 curated intelligence briefings related to this specific topic.
A strategic reorientation in Southeast Asian bio-manufacturing is slashing the cost of orphan drugs. By integrating modular GMP facilities and regulatory harmonization, the region is moving from generic biologics to high-value, low-volume rare disease breakthroughs.
